Takeda Pharmaceutical Company Limited (TAK) Advances γδ T Cell Cancer Treatments

We recently published 11 Best Cancer Stocks to Buy Right Now. Takeda Pharmaceutical Company Limited is placed tenth among them.

Takeda Pharmaceutical Company Limited (NYSE:TAK), a global biopharmaceutical leader, is advancing cancer treatment through novel immuno-oncology strategies focused on the innate immune system. A major development is the company’s planned acquisition of Adaptate Biotherapeutics, which specializes in gamma delta (γδ) T cell engager therapies for solid tumors.

The company also received a positive CHMP opinion in Europe for ADCETRIS (brentuximab vedotin) for advanced Hodgkin lymphoma, enhancing its oncology portfolio. Additionally, Takeda Pharmaceutical Company Limited (NYSE:TAK) presented encouraging clinical data for rusfertide at the 2025 ASCO Annual Meeting, highlighting ongoing late-stage pipeline progress in cancer and related diseases.

Takeda Pharmaceutical Company Limited (TAK) Advances γδ T Cell Cancer Treatments

A hand holding cancer cells with a magnifying glass, highlighting the company’s target of curing diseases.

Takeda Pharmaceutical Company Limited (NYSE:TAK)’s strategic focus emphasizes building an immuno-oncology portfolio around innate immunity, including γδ T cells and natural killer (NK) cells. Through acquisitions and R&D collaborations, the company is integrating cutting-edge platforms to develop innovative cancer therapies.

While we acknowledge the risk and potential of TAK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TAK and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.